Coagulopathy After Cardiopulmonary Bypass in Jehovah’s Witness Patients: Management of Two Cases Using Fractionated Components and Factor VIIa

@article{Sniecinski2007CoagulopathyAC,
  title={Coagulopathy After Cardiopulmonary Bypass in Jehovah’s Witness Patients: Management of Two Cases Using Fractionated Components and Factor VIIa},
  author={R. Sniecinski and E. Chen and J. Levy and F. Szlam and K. Tanaka},
  journal={Anesthesia & Analgesia},
  year={2007},
  volume={104},
  pages={763-765}
}
BACKGROUND:Changes in the Jehovah's Witness (JW) blood refusal policy now give members the personal choice to accept certain processed fractions of blood, such as factor concentrates and cryoprecipitate. METHODS:Two JW patients undergoing complex aortic surgery who developed severe microvascular bleeding after prolonged use of cardiopulmonary bypass were treated with recombinant activated factor VII, cryoprecipitate, and antithrombin concentrate. RESULTS:Cardiopulmonary bypass-induced… Expand
21 Citations
Prophylactic use of factor IX concentrate in a Jehovah's Witness patient.
Bleeding and management of coagulopathy.
Optimal care for patients who are Jehovah's Witnesses.
Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery.
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
  • M. Ragni
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2013
Overcoming Challenges in the Management of Critical Events During Cardiopulmonary Bypass
...
1
2
3
...

References

SHOWING 1-10 OF 15 REFERENCES
Multidisciplinary management of a Jehovah’s Witness patient for the removal of a renal cell carcinoma extending into the right atrium
Activation of coagulation and fibrinolysis during cardiothoracic operations.
Dosing with recombinant factor viia based on current evidence.
...
1
2
...